Biomarkers for the early diagnosis of sepsis.
10.3760/cma.j.issn.2095-4352.2019.03.026
- Author:
Zhou YUAN
1
;
Ruiqiang ZHENG
2
;
Qihong CHEN
2
;
Xiaoming WANG
1
Author Information
1. Clinical Medical College, Yangzhou University, Yangzhou 225001, Jiangsu, China.
2. Department of Critical Care Medicine, Northern Jiangsu People's Hospital, Yangzhou 225001, Jiangsu, China. Corresponding author: Zheng Ruiqiang, Email: 13952721411@163.com.
- Publication Type:Journal Article
- MeSH:
Biomarkers;
Early Diagnosis;
Humans;
Prognosis;
Sensitivity and Specificity;
Sepsis/diagnosis*
- From:
Chinese Critical Care Medicine
2019;31(3):381-384
- CountryChina
- Language:Chinese
-
Abstract:
Sepsis is the main cause of higher morbidity and mortality in hospitalized patients. Rapid recognition of sepsis as the cause of deterioration is desirable, so effective treatment can be initiated rapidly. More than 170 different biomarkers have been assessed for potential use in sepsis, more for prognosis than for diagnosis. None have sufficient specificity or sensitivity to be routinely employed in clinical practice. Therefore, it is essential for clinicians to seek more specific and sensitive biomarkers to early identify and diagnosis of sepsis patients, and further assess the severity and predict prognosis. Thus, combined biomarkers may be more effective than a single biomarker. This article focused on the current novel biomarkers of sepsis and their potential use at the bedside to guide clinical decision-making.
